GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Stopped No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab.
Conditions
- Pancreatic Adenocarcinoma
- Esophageal Adenocarcinoma
- Esophageal Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Triple Negative Breast Cancer
- Castration-resistant Prostate Cancer
- Microsatellite Stable Colorectal Cancer
- Non-small Cell Lung Cancer
- Small-cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
Interventions
- DRUG: GB1275
- DRUG: nab-paclitaxel and gemcitabine
- DRUG: pembrolizumab
Sponsor
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Collaborators